Suppliers and packagers for generic pharmaceutical drug: GEPOTIDACIN MESYLATE

GEPOTIDACIN MESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230	NDA	GlaxoSmithKline LLC	0173-0922-38	8 TABLET, FILM COATED in 1 BOTTLE (0173-0922-38)	2025-03-25
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230	NDA	GlaxoSmithKline LLC	0173-0922-45	20 TABLET, FILM COATED in 1 BOTTLE (0173-0922-45)	2025-03-25

Suppliers for the Pharmaceutical Drug: GEPOTIDACIN MESYLATE

Last updated: August 3, 2025

Introduction

Gepotidacin Mesylate is a novel antibiotic belonging to the triazaquinolione class, developed to combat resistant bacterial infections, notably those caused by Escherichia coli and Neisseria gonorrhoeae. As antimicrobial resistance escalates globally, the demand for innovative antibiotics like gepotidacin has intensified. Ensuring a reliable supply chain requires identifying credible suppliers capable of manufacturing high-quality gepotidacin mesylate at scale. This report provides a comprehensive overview of current suppliers, their capabilities, and strategic considerations pertinent to stakeholders in the pharmaceutical industry.

Manufacturers and Contract Manufacturing Organizations (CMOs)

1. Forging Ahead: Primary Innovators and Suppliers

Currently, the development and commercialization of gepotidacin mesylate involve a few key industry players:

• GSK (GlaxoSmithKline):
  As the primary developer, GSK holds active patent rights and manufacturing rights for gepotidacin formulations. The company's integrated supply chain spans R&D to manufacturing, with partnerships across global facilities to scale up production in response to clinical and commercial demands.

• Adamis Pharmaceuticals:
  Known for contract manufacturing in antimicrobial agents, Adamis possesses capabilities for synthesizing complex molecules like gepotidacin mesylate, especially in early-stage production tailored for clinical trials.

• Contract Manufacturing Organizations (CMOs):
  Several CMOs with expertise in small-molecule synthesis and mesylate salt formulations serve as potential suppliers for clinical and commercial scale-up:

  • Lonza Group:
    A leading CMO with extensive experience in active pharmaceutical ingredient (API) synthesis, including complex antibiotics. Lonza's facilities in Switzerland and the US are equipped for GMP manufacturing of mesylate salts.

  • Thermo Fisher Scientific:
    Offers custom synthesis services, including high-potency API production, with capabilities for scale-up and formulation development.

  • ABBVIE Contract Manufacturing:
    Has capabilities in small-molecule API production, particularly for complex antibiotics, with approved facilities in the US and Europe.

2. Licensing and Supply Agreements

GSK’s strategy involves licensing gepotidacin production to specialized CMOs under strict quality and supply agreements. Manufacturing partners are selected through rigorous qualification processes to meet regulatory standards, including the US FDA and EMA approvals.

3. Supply Chain Considerations

• Raw Materials & Intermediates:
  The synthesis of gepotidacin mesylate necessitates high-purity intermediates. Suppliers of key raw materials include specialized chemical companies such as:

  • Alfa Aesar and Sigma-Aldrich:
    Global suppliers of pharmaceutical-grade chemicals suitable for mesylate salt synthesis.

  • Cambridge Isotope Laboratories:
    Supplies isotopically labeled intermediates if needed for tracking or research.

• Active Ingredient Synthesis Complexity:
  The process involves multiple steps—cyclization, substitution, and salt formation—requiring advanced chemical expertise and strict quality control.

Key Suppliers’ Capabilities and Certifications

Supplier	Capabilities	Certifications	Notes
Lonza	GMP API synthesis, complex molecule manufacturing	cGMP, ISO 9001	Extensive experience in antibiotics
Thermo Fisher Scientific	Custom chemical synthesis, high-volume batch production	GMP, FDA-G-lined facilities	Known for scalability and quality
Alfa Aesar/Sigma-Aldrich	Raw materials, specialty chemicals	ISO 9001, FDA acceptable	Reliable supply chain for reagents
GSK	In-house production, licensed manufacturing	GMP, FDA, EMA approvals	Proprietary processes for gepotidacin

Emerging and Future Suppliers

The pipeline for gepotidacin mesylate may expand as new biosynthetic innovations emerge. Notably:

• Emerging biotech firms specializing in antibiotic synthesis might develop novel manufacturing techniques, potentially reducing costs and lead times.
• Regional suppliers in China and India are increasingly investing in GMP-compliant facilities, positioning themselves as alternative sources, subject to stringent regulatory validation.

Strategic Considerations for Stakeholders

• Regulatory Compliance: Ensuring suppliers hold necessary certifications (GMP, ISO, FDA approval) is critical.
• Supply Security: Diversifying suppliers reduces dependency risks amid global disruptions.
• Quality Assurance: Rigorous audits and batch testing are essential before qualifying suppliers.
• Intellectual Property Rights: Clarify licensing and proprietary process agreements to prevent legal complications.

Conclusion

Currently, the primary supplier for gepotidacin mesylate is GSK, leveraging in-house manufacturing and strategic partnerships with CMOs such as Lonza and Thermo Fisher Scientific. These suppliers possess the technical capabilities, certifications, and capacity to meet both clinical and commercial demands. Sourcing from reliable, validated suppliers ensures quality, regulatory compliance, and supply stability—imperative amidst the rising necessity for novel antibiotics.

---

Key Takeaways

• GSK is the principal developer and supplier of gepotidacin mesylate, supported by CMOs with proven expertise in complex antibiotic synthesis.
• Top-tier companies like Lonza and Thermo Fisher Scientific offer scalable GMP manufacturing suitable for clinical and commercial production.
• The supply chain hinges on high-quality raw materials from specialized chemical suppliers such as Sigma-Aldrich.
• Diversification and thorough qualification of suppliers mitigate risks associated with supply chain disruptions.
• Future supply landscape may diversify as regional manufacturers expand capacity under rigorous quality standards.

---

FAQs

1. Which companies are currently licensed to manufacture gepotidacin mesylate?
GSK leads the manufacturing efforts, often partnering with CMOs like Lonza and Thermo Fisher Scientific to produce gepotidacin mesylate at various scales.

2. What are the primary challenges in sourcing gepotidacin mesylate?
Challenges include ensuring GMP compliance, managing complex chemical synthesis, securing high-quality raw materials, and maintaining supply chain stability amid global logistics fluctuations.

3. Are there regional suppliers capable of producing gepotidacin mesylate?
Yes, regional manufacturers in North America, Europe, and Asia are developing capabilities, but rigorous validation and regulatory approvals are necessary before qualification.

4. What regulatory aspects influence supplier selection?
Suppliers must hold GMP certifications, comply with FDA and EMA standards, and have documented quality assurance processes to meet regulatory requirements.

5. How might future developments impact the supply chain for gepotidacin mesylate?
Innovations in synthesis processes, regional manufacturing expansion, and strategic licensing could diversify and stabilize supply sources, improving access and cost-efficiency.

---

Sources:

[1] GlaxoSmithKline, Gepotidacin Development Program, 2023.
[2] Lonza Group, API Manufacturing Capabilities, 2023.
[3] Thermo Fisher Scientific, Contract Manufacturing Services, 2023.
[4] Sigma-Aldrich, High-Purity Chemicals and Intermediates, 2023.
[5] U.S. Food and Drug Administration, Guidelines for GMP Compliance, 2023.